Clinical Trials Logo

Peripheral T-cell Lymphoma clinical trials

View clinical trials related to Peripheral T-cell Lymphoma.

Filter by:

NCT ID: NCT04668690 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Start date: January 1, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, active controlled, multi-center, phase 3 clinical study to compare the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with Chidamide in patients with relapsed/refractory Peripheral T Cell Lymphoma (PTCL).

NCT ID: NCT04615468 Not yet recruiting - Clinical trials for Peripheral T-cell Lymphoma

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma(PTCL)

Start date: December 1, 2020
Phase: Phase 2
Study type: Interventional

This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with relapse/refactory peripheral T-cell lymphoma who have received at least 1 lines of therapeutic schedules. TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.

NCT ID: NCT04569032 Active, not recruiting - Clinical trials for Peripheral T-cell Lymphoma

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Start date: November 12, 2020
Phase: Phase 2
Study type: Interventional

This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.

NCT ID: NCT04548700 Terminated - Clinical trials for Peripheral T Cell Lymphoma

Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL

Start date: December 24, 2020
Phase: Phase 1
Study type: Interventional

This is a multicentre, open-label, single-arm, phase Ib clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine and Prednisone in the frontline treatment of patients with peripheral T cell lymphoma (PTCL).

NCT ID: NCT04526834 Active, not recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

CERTAIN
Start date: September 8, 2021
Phase: Phase 1
Study type: Interventional

This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma

NCT ID: NCT04512534 Recruiting - Clinical trials for Peripheral T-cell Lymphoma

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma

Sincerely20
Start date: November 13, 2020
Phase: Phase 2
Study type: Interventional

This is a single-center, single-arm, phase 2 study to evaluate the efficacy and safety of Anti-PD-1 antibody(Sintilimab) plus HDAC inhibitor(Chidamide) in patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL).

NCT ID: NCT04489264 Recruiting - Clinical trials for Peripheral T Cell Lymphoma

The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma

Start date: November 30, 2020
Phase:
Study type: Observational

The role of autologous stem cell transplantation (ASCT) in the first remission (CR1 & PR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the clinical outcomes of patients with newly diagnosed PTCL in CR1 and PR1.

NCT ID: NCT04480125 Recruiting - Clinical trials for Peripheral T-cell Lymphoma

Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

Start date: June 20, 2020
Phase: Phase 2
Study type: Interventional

This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.

NCT ID: NCT04480099 Active, not recruiting - Clinical trials for Peripheral T-cell Lymphoma

Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Start date: July 29, 2020
Phase: Phase 2
Study type: Interventional

This prospective,multi-center,open-label, controlled study will evaluate the efficacy and safety of targeted drug in combination with CHOP in treatment of newly diagnosed peripheral T-cell lymphoma.

NCT ID: NCT04470141 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma

A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma

Start date: August 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of SHC014748M in patients with relapsed or refractory relapsed or refractory Peripheral T Cell Lymphoma.